Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411311 | 0.92 | NT5E (0.36) | METAP2L3MBTL1TMEM97SIGMAR1BCHE | |
| SCHEMBL9110670 | 0.82 | L3MBTL1 (0.54) | METAP2L3MBTL1BCHEPDPK1MTOR | |
| SCHEMBL20626555 | 0.82 | L3MBTL1 (0.54) | METAP2L3MBTL1BCHEPDPK1MTOR | |
| SCHEMBL535106 | 0.82 | L3MBTL1 (0.54) | METAP2L3MBTL1BCHEPDPK1MTOR | |
| SCHEMBL9908823 | 0.82 | L3MBTL1 (0.54) | METAP2L3MBTL1BCHEPDPK1MTOR | |
| SCHEMBL15196691 | 0.82 | L3MBTL1 (0.54) | METAP2L3MBTL1BCHEPDPK1MTOR | |
| SCHEMBL402647 | 0.82 | PKM (0.35) | METAP2 | |
| SCHEMBL5460304 | 0.82 | PKM (0.35) | METAP2 | |
| SCHEMBL12729386 | 0.80 | ALDH1A1 (0.37) | METAP2L3MBTL1BCHE | |
| SCHEMBL1648065 | 0.80 | ALDH1A1 (0.37) | METAP2L3MBTL1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | METAP2 1858/4885L3MBTL1 4789/4885TMEM97 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.